Journal Home > Volume 15 , Issue 2
Nano Research 2022, 15(2): 1645-1653 https://doi.org/10.1007/s12274-021-3713-4
Research Article | Issue | Published: 12 August 2021

Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection

Show Author's Information Xin Li,  Chao Pan( ),  Peng Sun,  Zhehui Peng,  Erling Feng,  Jun Wu,  Hengliang Wang( ),  Li Zhu( )
State Key Laboratory of Pathogen and Biosecurity Beijing Institute of BiotechnologyBeijing 100071 China
Keywords:
Shigela flexneri 2a, O-polysaccharide, virus-like particle, SpyTag/SpyCatcher system, nanoconjugate vaccines
Topics:
Vaccines
Cite this article:
Li X, Pan C, Sun P, et al. Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection. Nano Research, 2022, 15(2): 1645-1653. https://doi.org/10.1007/s12274-021-3713-4
Download citation
EndNote(RIS)
BibTeX

618

Views

63

Downloads

Citations

24

Crossref

25

WoS

22

Scopus

3

CSCD

Abstract Full text Electronic supplementary material About this article

Conjugate vaccines represent one of the most effective means for controlling the occurrence of bacterial diseases. Although nanotechnology has been greatly applied in the field of vaccines, it is seldom used for conjugate vaccine research because it is very difficult to connect polysaccharides and nanocarriers. In this work, an orthogonal and modular biosynthesis method was used to produce nanoconjugate vaccines using the SpyTag/SpyCatcher system. When SpyTag/SpyCatcher system is combined with protein glycosylation technology, bacterial O-polysaccharide obtained from Shigela flexneri 2a can be conjugated onto the surfaces of different virus-like particles (VLPs) in a biocompatible and controlled manner. After confirming the excellent lymph node targeting and humoral immune activation abilities, these nanoconjugate vaccines further induced efficient prophylactic effects against infection in a mouse model. These results demonstrated that natural polysaccharide antigens can be easily connected to VLPs to prepare highly efficient nanoconjugate vaccines. To the best of the researchers' knowledge, this is the first time VLP-based nanoconjugate vaccines are produced efficiently, and this strategy could be applied to develop various pathogenic nanoconjugate vaccines.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Orthogonal modular biosynthesis of nanoscale conjugate vaccines for vaccination against infection

Show Author's information Xin Li, Chao Pan( ), Peng Sun, Zhehui Peng, Erling Feng, Jun Wu, Hengliang Wang( ), Li Zhu( )
State Key Laboratory of Pathogen and Biosecurity Beijing Institute of BiotechnologyBeijing 100071 China

Abstract

Conjugate vaccines represent one of the most effective means for controlling the occurrence of bacterial diseases. Although nanotechnology has been greatly applied in the field of vaccines, it is seldom used for conjugate vaccine research because it is very difficult to connect polysaccharides and nanocarriers. In this work, an orthogonal and modular biosynthesis method was used to produce nanoconjugate vaccines using the SpyTag/SpyCatcher system. When SpyTag/SpyCatcher system is combined with protein glycosylation technology, bacterial O-polysaccharide obtained from Shigela flexneri 2a can be conjugated onto the surfaces of different virus-like particles (VLPs) in a biocompatible and controlled manner. After confirming the excellent lymph node targeting and humoral immune activation abilities, these nanoconjugate vaccines further induced efficient prophylactic effects against infection in a mouse model. These results demonstrated that natural polysaccharide antigens can be easily connected to VLPs to prepare highly efficient nanoconjugate vaccines. To the best of the researchers' knowledge, this is the first time VLP-based nanoconjugate vaccines are produced efficiently, and this strategy could be applied to develop various pathogenic nanoconjugate vaccines.

Keywords: Shigela flexneri 2a, O-polysaccharide, virus-like particle, SpyTag/SpyCatcher system, nanoconjugate vaccines

References(44)

1

Irvine, D. J.; Swartz, M. A.; Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nat. Mater. 2013, 12, 978–990.
DOI Google Scholar
2

Karch, C. P.; Burkhard, P. Vaccine technologies: From whole organisms to rationally designed protein assemblies. Biochem. Pharmacol. 2016, 120, 1–14.
DOI Google Scholar
3

Schmidt, S. T.; Foged, C.; Korsholm, K. S.; Rades, T. Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators. Pharmaceutics 2016, 8, 7.
DOI Google Scholar
4

Poteet, E.; Lewis, P.; Chen, C. Y.; Ho, S. O.; Do, T.; Chiang, S.; Labranche, C.; Montefiori, D.; Fujii, G.; Yao, Q. Z. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine 2016, 34, 5886–5894.
DOI Google Scholar
5

Vartak, A.; Sucheck, S. J. Recent advances in subunit vaccine carriers. Vaccines 2016, 4, 12.
DOI Google Scholar
6

Dowling, D. J.; Scott, E. A.; Scheid, A.; Bergelson, I.; Joshi, S.; Pietrasanta, C.; Brightman, S.; Sanchez-Schmitz, G.; van Haren, S. D.; Ninkovic, J. et al. Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses. J. Allergy Clin. Immunol. 2017, 140, 1339–1350.
DOI Google Scholar
7

Lynn, G. M.; Laga, R.; Darrah, P. A.; Ishizuka, A. S.; Balaci, A. J.; Dulcey, A. E.; Pechar, M.; Pola, R.; Gerner, M. Y.; Yamamoto, A. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 2015, 33, 1201–1210.
DOI Google Scholar
8

Ebrahimian, M.; Hashemi, M.; Maleki, M.; Hashemitabar, G.; Abnous, K.; Ramezani, M.; Haghparast, A. Co-delivery of dual toll-like receptor agonists and antigen in poly(lactic-Co-glycolic) acid/polyethylenimine cationic hybrid nanoparticles promote efficient in vivo immune responses. Front. Immunol. 2017, 8, 1077.
DOI Google Scholar
9

Christensen, D. Vaccine adjuvants: Why and how. Hum. Vaccin. Immunother 2016, 12, 2709–2711.
DOI Google Scholar
10

Banday, A. H.; Jeelani, S.; Hruby, V. J. Cancer vaccine adjuvants- recent clinical progress and future perspectives. Immunopharmacol. Immunotoxicol. 2015, 37, 1–11.
DOI Google Scholar
11

Xu, H.; Huang, J.; Liu, Z. L.; Li, X.; Wang, K. F.; Feng, E. L.; Wu, J.; Zhu, L.; Yao, K. H.; Pan, C. et al. Expression of Bordetella pertussis antigens fused to different vectors and their effectiveness as vaccines. Vaccines (Basel) 2021, 9, 542.
DOI Google Scholar
12

Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25, 1159–1164.
DOI Google Scholar
13

Irvine, D. J.; Hanson, M. C.; Rakhra, K.; Tokatlian, T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 2015, 115, 11109–11146.
DOI Google Scholar
14

Molino, N. M.; Neek, M.; Tucker, J. A.; Nelson, E. L.; Wang, S. W. Display of DNA on nanoparticles for targeting antigen presenting cells. ACS Biomater. Sci. Eng. 2017, 3, 496–501.
DOI Google Scholar
15

Bachmann, M. F.; Jennings, G. T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010, 10, 787–796.
DOI Google Scholar
16

Win, S. J.; Ward, V. K.; Dunbar, P. R.; Young, S. L.; Baird, M. A. Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol. Cell Biol. 2011, 89, 681–688.
DOI Google Scholar
17

Lin, A. Y.; Lunsford, J.; Bear, A. S.; Young, J. K.; Eckels, P.; Luo, L.; Foster, A. E.; Drezek, R. A. High-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitro. Nanoscale Res. Lett. 2013, 8, 72.
DOI Google Scholar
18

An, M.; Li, M.; Xi, J. C.; Liu, H. P. Silica nanoparticle as a lymph node targeting platform for vaccine delivery. ACS Appl. Mater. Interfaces 2017, 9, 23466–23475.
DOI Google Scholar
19

Kang, S.; Ahn, S.; Lee, J.; Kim, J. Y.; Choi, M.; Gujrati, V.; Kim, H.; Kim, J.; Shin, E. C.; Jon, S. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J. Control. Release 2017, 256, 56–67.
DOI Google Scholar
20

Rahimian, S.; Kleinovink, J. W.; Fransen, M. F.; Mezzanotte, L.; Gold, H.; Wisse, P.; Overkleeft, H.; Amidi, M.; Jiskoot, W.; Lowik, C. W. et al. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: In vivo tracking and evaluation of antigen-specific CD8+ T cell immune response. Biomaterials 2015, 37, 469–477.
DOI Google Scholar
21

Wen, R.; Umeano, A. C.; Chen, P. P.; Farooqi, A. A. Polymer-based drug delivery systems for cancer. Crit. Rev. Ther. Drug Carrier Syst. 2018, 35, 521–553.
DOI Google Scholar
22

De Gregorio, E.; Rappuoli, R. From empiricism to rational design: A personal perspective of the evolution of vaccine development. Nat. Rev. Immunol. 2014, 14, 505–514.
DOI Google Scholar
23

Pushko, P.; Pumpens, P.; Grens, E. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 2013, 56, 141–165.
DOI Google Scholar
24

Smith, M. T.; Hawes, A. K.; Bundy, B. C. Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr. Opin. Biotechnol. 2013, 24, 620–626.
DOI Google Scholar
25

Mateu, M. G. Virus engineering: Functionalization and stabilization. Protein Eng. Des. Sel. 2011, 24, 53–63.
DOI Google Scholar
26
Strable, E.; Finn, M. G. Chemical modification of viruses and virus- like particles. In Viruses and Nanotechnology. Manchester, M.; Steinmetz, M. F., Eds.; Springer: Berlin, 2009; pp 1–21.https://doi.org/10.1007/978-3-540-69379-6_1
DOI
27

Sletten, E. M.; Bertozzi, C. R. Bioorthogonal chemistry: Fishing for selectivity in a sea of functionality. Angew. Chem. , Int. Ed. 2009, 48, 6974–6998.
DOI Google Scholar
28

Zakeri, B.; Fierer, J. O.; Celik, E.; Chittock, E. C.; Schwarz-Linek, U.; Moy, V. T.; Howarth, M. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 2012, 109, E690–E697.
DOI Google Scholar
29

Li, L.; Fierer, J. O.; Rapoport, T. A.; Howarth, M. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide Tag. J. Mol. Biol. 2014, 426, 309–317.
DOI Google Scholar
30

Brune, K. D.; Leneghan, D. B.; Brian, I. J.; Ishizuka, A. S.; Bachmann, M. F.; Draper, S. J.; Biswas, S.; Howarth, M. Plug-and-display: Decoration of virus-like particles via isopeptide bonds for modular immunization. Sci. Rep. 2016, 6, 19234.
DOI Google Scholar
31

Janitzek, C. M.; Matondo, S.; Thrane, S.; Nielsen, M. A.; Kavishe, R.; Mwakalinga, S. B.; Theander, T. G.; Salanti, A.; Sander, A. F. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses. Malar. J. 2016, 15, 545.
DOI Google Scholar
32

Brune, K. D.; Buldun, C. M.; Li, Y. Y.; Taylor, I. J.; Brod, F.; Biswas, S.; Howarth, M. Dual plug-and-display synthetic assembly using orthogonal reactive proteins for twin antigen immunization. Bioconjugate Chem. 2017, 28, 1544–1551.
DOI Google Scholar
33

Thrane, S.; Janitzek, C. M.; Matondo, S.; Resende, M.; Gustavsson, T.; de Jongh, W. A.; Clemmensen, S.; Roeffen, W.; van de Vegte- Bolmer, M.; van Gemert, G. J. et al. Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J. Nanobiotechnol. 2016, 14, 30.
DOI Google Scholar
34

Sáfadi, M. A.; Bettinger, J. A.; Maturana, G. M.; Enwere, G.; Borrow, R.; Global Meningococcal, I. Evolving meningococcal immunization strategies. Exp. Rev. Vaccin. 2015, 14, 505–517.
DOI Google Scholar
35

Martin, L. B.; Simon, R.; MacLennan, C. A.; Tennant, S. M.; Sahastrabuddhe, S.; Khan, M. I. Status of paratyphoid fever vaccine research and development. Vaccine 2016, 34, 2900–2902.
DOI Google Scholar
36

Bröker, M.; Berti, F.; Costantino, P. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum. Vacc. Immunother. 2016, 12, 1808–1824.
Google Scholar
37

Kuberan, B.; Linhardt, R. J. Carbohydrate based vaccines. Curr. Org. Chem. 2000, 4, 635–677.
DOI Google Scholar
38

Pan, C.; Wu, J.; Qing, S.; Zhang, X.; Zhang, L. L.; Yue, H.; Zeng, M.; Wang, B.; Yuan, Z.; Qiu, Y. F. et al. Biosynthesis of self-assembled proteinaceous nanoparticles for vaccination. Adv. Mater. 2020, 32, 2002940.
DOI Google Scholar
39
Peng, Z. H.; Wu, J.; Wang, K. F.; Li, X.; Sun, P.; Zhang, L. L.; Huang, J.; Liu, Y.; Hua, X. T.; Yu, Y. S. et al. Production of a promising biosynthetic self-assembled nanoconjugate vaccine against Klebsiella pneumoniae serotype O2 in a general Escherichia coli host. Adv. Sci., in press, DOI: 10.1002/advs.202100549.https://doi.org/10.1002/advs.202100549
DOI
40

Pan, C.; Sun, P.; Liu, B.; Liang, H. Y.; Peng, Z. H.; Dong, Y.; Wang, D. S.; Liu, X. K.; Wang, B.; Zeng, M. et al. Biosynthesis of conjugate vaccines using an O-linked glycosylation system. mBio 2016, 7, e00443-16.
DOI Google Scholar
41

Hanson, C. M.; George, A. M.; Sawadogo, A.; Schreiber, B. Is freezing in the vaccine cold chain an ongoing issue? A literature review. Vaccine 2017, 35, 2127–2133.
DOI Google Scholar
42

Paulis, L. E.; Mandal, S.; Kreutz, M.; Figdor, C. G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013, 25, 389–395.
DOI Google Scholar
43

Vinuesa, C. G.; Linterman, M. A.; Yu, D.; MacLennan, I. C. M. Follicular helper T cells. Annu. Rev. Immunol. 2016, 34, 335–368.
DOI Google Scholar
44

McHeyzer-Williams, L. J.; Milpied, P. J.; Okitsu, S. L.; McHeyzer- Williams, M. G. Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat. Immunol. 2015, 16, 296–305.
DOI Google Scholar
File
12274_2021_3713_MOESM1_ESM.pdf (2.3 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 16 April 2021
Revised: 17 June 2021
Accepted: 24 June 2021
Published: 12 August 2021
Issue date: February 2022

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021

Acknowledgements

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 81930122 and U20A20361) and the National Key Research and Development Project of China (No. 2021YFC2102101).

Return